Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
2.390
+0.050 (2.14%)
At close: Apr 2, 2025, 4:00 PM
2.360
-0.030 (-1.26%)
After-hours: Apr 2, 2025, 6:32 PM EDT
Vistagen Therapeutics Revenue
Vistagen Therapeutics had revenue of $234.00K in the quarter ending December 31, 2024, a decrease of -43.07%. This brings the company's revenue in the last twelve months to $698.00K, down -33.07% year-over-year. In the fiscal year ending March 31, 2024, Vistagen Therapeutics had annual revenue of $1.06M, down -568.72%.
Revenue (ttm)
$698.00K
Revenue Growth
-33.07%
P/S Ratio
104.84
Revenue / Employee
$17,450
Employees
40
Market Cap
68.98M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
VTGN News
- 14 days ago - Vistagen to Present at the 2025 Anxiety and Depression Association Conference - Business Wire
- 4 weeks ago - Vistagen to Participate in Stifel 2025 Virtual CNS Forum - Business Wire
- 5 weeks ago - Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference - Business Wire
- 6 weeks ago - Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication - Seeking Alpha
- 6 weeks ago - Vistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update - Business Wire
- 7 weeks ago - Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025 - Business Wire
- 2 months ago - Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain - Business Wire